Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4865639 | 0.98 | HPGD (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1920997 | 0.90 | HPGD (0.49) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL15342623 | 0.90 | HPGD (0.49) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1921000 | 0.90 | HPGD (0.49) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4339378 | 0.88 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL24765156 | 0.84 | HPGD (0.57) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL2770208 | 0.84 | GPR119 (0.61) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL85477 | 0.84 | HPGD (0.57) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL11966009 | 0.84 | HPGD (0.57) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL9834472 | 0.83 | HPGD (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403144-B2 | HECT E3 ligase inhibitors and uses thereof | IFOM —FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2025-09-02 | — | — | US | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| EP-3976185-B1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM ST FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS (IT) | 2024-02-14 | — | — | EP | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-20220339163-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2022-10-27 | — | — | US | disclosed |
| EP-3976185-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - Fondazione Istituto FIRC di Oncologia Molecolare (IT) | 2022-04-06 | — | — | EP | disclosed |
| US-11267826-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-2004669-A1 | AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-12-24 | — | — | EP | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007118830-A1 | AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-10-25 | — | — | WO | disclosed |
| EP-1741702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
| EP-1732566-A2 | 6-AZAINDOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097129-A2 | 6-AZAINDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-20 | — | — | WO | disclosed |
| EP-0495750-A2 | Heterocyclic hydroxylamine | CIBA-GEIGY AG (CH) | 1992-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | HPGD 1998/4885RECQL 4172/4885EPHX1 3549/4885 |
| US-11267826-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | HPGD 2719/4885RECQL 2164/4885EPHX1 4100/4885 |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | HPGD 770/4885RECQL 1764/4885EPHX1 360/4885 |
| US-20220339163-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | NEDD4, ITCH, UBE3A | HPGD 3455/4885RECQL 2349/4885EPHX1 1225/4885 |
| US-12403144-B2 | HECT E3 ligase inhibitors and uses thereof | NEDD4, ITCH, UBE3A | HPGD 3455/4885RECQL 2349/4885EPHX1 1225/4885 |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | HPGD 431/4885RECQL 4261/4885EPHX1 601/4885 |
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | MAPK1, NOS1, NOS2 | HPGD 55/4885RECQL 4400/4885EPHX1 385/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | HPGD 1010/4885RECQL 2003/4885EPHX1 294/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | HPGD 1998/4885RECQL 4172/4885EPHX1 3549/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | HPGD 1998/4885RECQL 4172/4885EPHX1 3549/4885 |
| US-20080064715-A1 | 6-Azaindole Compound | RELA, NFKBIA, GPR119 | HPGD 3042/4885RECQL 1543/4885EPHX1 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.